Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2024-202457

Published: 2024

Journal Articles

MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase Ⅰ, First-in-Human, Open-Label, Dose Escalation Study

Gang An, Lijie Xing, Wenming Chen, Yan Zhang, Wen Gao, Lu-Gui Qiu, Guojin Wu, Jinying Ning, Min Wei, Feng Li

Blood (2024) 144 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2024-199423

Published: 2024

Journal Articles

Synergistic Induction of Senescence-Driven Immune Responses and Myeloma Cell Cytotoxicity By CDK4/6 Inhibitors and Daratumumab Combination Therapy

Shiyi Xie, Zhen Yu, Mu Hao, Lu-Gui Qiu, Mariateresa Fulciniti, Nikhil C. Munshi, Yan Xu

Blood (2024) 144 (Supplement 1): 1410.

https://doi.org/10.1182/blood-2024-200479

Published: 2024

Journal Articles

TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

Yuting Yan, Dandan Shan, Ying Yu, Weihao Chen, Xinyi Zhang, Xiong Wenjie, Tingyu Wang, Mu Hao, Gang An, Lu-Gui Qiu, Zhen Yu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 832.

https://doi.org/10.1182/blood-2024-201941

Published: 2024

Journal Articles

Prognostic Significance of Monoclonal Gammopathy in Chronic Lymphocytic Leukemia Under Different Therapeutic Backgrounds

Yuting Yan, Bolin Yuan, Tingyu Wang, Ying Yu, Weihao Chen, Dandan Shan, Xiong Wenjie, Gang An, Dehui Zou, Lu-Gui Qiu, Qiong Wang, Shuhua Yi

Blood (2024) 144 (Supplement 1): 1861.

https://doi.org/10.1182/blood-2024-204668

Published: 2024

Journal Articles

First-in-Human, Phase Ia , Dose Escalation, Monotherapy Study of QLS32015, a Novel GPRC5D×CD3 T-Cell Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Lu-Gui Qiu, Gang An, Baijun Fang, Xiaobing Huang, Yan Xu, Yuzhang Liu, Feifei Che, Xinai Yang, Xianlin Duan, Peng Shao, Xiaoyan Kang

Blood (2024) 144 (Supplement 1): 1990.

https://doi.org/10.1182/blood-2024-201960

Published: 2024

Journal Articles

Critical Roles of LILRB4 in Promoting PIM Kinase Mediated Cell Proliferation and Tumorigenesis in Multiple Myeloma

Yijie Wang, Jingyuan Ma, Xiyue Sun, Lixin Gong, Lanting Liu, Gang An, Lu-Gui Qiu, Mu Hao

Blood (2024) 144 (Supplement 1): 3262.

https://doi.org/10.1182/blood-2024-202920

Published: 2024

Journal Articles

Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom's Macroglobulinemia Undergoing Ibrutinib Monotherapy

Hao Sun, Romanos Sklavenitis-Pistofidis, Xia Liu, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Andres Felipe Ramirez Gamero, Catherine A. Flynn, Christopher J Patterson, Mu Hao, Lu-Gui Qiu, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Shirong Liu, Steven P. Treon

Blood (2024) 144 (Supplement 1): 4338.

https://doi.org/10.1182/blood-2024-211597

Published: 2024

Journal Articles

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Yuntong Liu, Weiwei Sui, Rui Lyu, Chenxing DU, Shuaishuai Zhang, Tengteng Yu, Jingyu Xu, Wenqiang Yan, Yuting Yan, Wei Liu, Yi Wang, Qi Wang, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2024-200117

Published: 2024

Journal Articles

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Wenqiang Yan, Chenxing DU, Rui Lv, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2024-199913

Published: 2024

Journal Articles

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Blood (2024) 144 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2024-202324

Published: 2024

Journal Articles

Harnessing Ctdna to Predict Therapeutic Success in DLBCL: Insights from a Multicenter Prospective Study

Wei Liu, Changming Dong, Yi Wang, Ting Xie, Shunjin Zhang, Xiaoxia Wang, Jinghua Wu, Xiao Liu, Dehui Zou, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2024-204594

Published: 2024

Journal Articles

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Gang An, Zhongxia Huang, Aibin Liang, Baijun Fang, Hongmei Jing, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2024-206742

Published: 2024

Journal Articles

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2024) 144 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2024-197877

Published: 2024

Journal Articles

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Jingyu Xu, Shuaishuai Zhang, Wenqiang Yan, Yuntong Liu, Rui Lyu, Chenxing DU, Weiwei Sui, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2024-200847

Published: 2024

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

A Novel Indirubin-3-Monoxime Derivative Enhance Immune Cell Mediated Cytotoxicity in Multiple Myeloma

Xiaoyu Zhang, Xiyue Sun, Lanting Liu, Zhen Yu, Lu-Gui Qiu, Mu Hao

Blood (2024) 144 (Supplement 1): 7467.

https://doi.org/10.1182/blood-2024-202892

Published: 2024

Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2024) 144 (Supplement 1): 886.

https://doi.org/10.1182/blood-2024-198147

Published: 2024

Journal Articles

Comparative Analysis of Patient Characteristics, Treatment Modalities, and Survival Outcomes in Chronic Lymphocytic Leukemia from China and the US

Yuting Yan, Yin Liu, Fan Yang, Jiamei Liu, Yanfei Chen, Ying Yu, Xiong Wenjie, Tingyu Wang, Zhijian Xiao, Jianxiang Wang, Thomas J. Kipps, Robert Peter Gale, Lu-Gui Qiu, Jifang Zhou, Shuhua Yi

Blood (2024) 144 (Supplement 1): 7820.

https://doi.org/10.1182/blood-2024-204512

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in China Multiple Myeloma Patients with Unmet Needs

Jian Cui, Dan Shen, Gang Liu, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 6908.

https://doi.org/10.1182/blood-2024-198949

Published: 2024

NARROW

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase Ⅰ, First-in-Human, Open-Label, Dose Escalation Study

Synergistic Induction of Senescence-Driven Immune Responses and Myeloma Cell Cytotoxicity By CDK4/6 Inhibitors and Daratumumab Combination Therapy

TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

Prognostic Significance of Monoclonal Gammopathy in Chronic Lymphocytic Leukemia Under Different Therapeutic Backgrounds

First-in-Human, Phase Ia , Dose Escalation, Monotherapy Study of QLS32015, a Novel GPRC5D×CD3 T-Cell Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Critical Roles of LILRB4 in Promoting PIM Kinase Mediated Cell Proliferation and Tumorigenesis in Multiple Myeloma

Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom's Macroglobulinemia Undergoing Ibrutinib Monotherapy

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Harnessing Ctdna to Predict Therapeutic Success in DLBCL: Insights from a Multicenter Prospective Study

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

A Novel Indirubin-3-Monoxime Derivative Enhance Immune Cell Mediated Cytotoxicity in Multiple Myeloma

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Comparative Analysis of Patient Characteristics, Treatment Modalities, and Survival Outcomes in Chronic Lymphocytic Leukemia from China and the US

Real-World Patient Characteristics and Outcomes in China Multiple Myeloma Patients with Unmet Needs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only